Showing results (41-50 of 86) with videos related to
Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2Richard W Joseph, Jeanette E Eckel-Passow, Ruchi Sharma, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2017
Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell CarcinomaThai Huu Ho, Payal Kapur, Jeanette E Eckel-Passow, et al.BMC Urology|March 23, 2017
BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumorJeanette E Eckel-Passow, Daniel J Serie, John C Cheville, et al.Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaRichard W Joseph, Ryan J Sullivan, Robyn Harrell, et al.Urologic Oncology|December 4, 2014
Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinomaThai H Ho, Payal Kapur, Richard W Joseph, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 31, 2015
Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific deathThai H Ho, Payal Kapur, Richard W Joseph, et al.Cancer Immunology Research|April 30, 2014
Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinomaRichard W Joseph, Mansi Parasramka, Jeanette E Eckel-Passow, et al.European Urology Focus|July 21, 2017
Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related DeathMansi Parasramka, Daniel J Serie, Yan W Asmann, et al.Cancer|December 20, 2011
NRAS mutation status is an independent prognostic factor in metastatic melanomaJohn A Jakob, Roland L Bassett, Chaan S Ng, et al.Pageof 9